首页> The Journal of Infectious Diseases> First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens

导出原文传递

翻译打印收藏纠错

第一作者： Nyombayire, Julien

作者： Nyombayire, Julien ^[1] ; Anzala, Omu ^[2] ; Gazzard, Brian ^[3] ; Karita, Etienne ^[4] ; Bergin, Philip ^[5] ; Hayes, Peter ^[6] ; Kopycinski, Jakub ^[7] ; Omosa-Manyonyi, Gloria ^[8] ; Jackson, Akil ; Bizimana, Jean ; Farah, Bashir ; Sayeed, Eddy ; Parks, Christopher L. ; Inoue, Makoto ; Hironaka, Takashi ; Hara, Hiroto ; Shu, Tsugumine ; Matano, Tetsuro ; Dally, Len ; Barin, Burc ; Park, Harriet ; Gilmour, Jill ; Lombardo, Angela ; Excler, Jean-Louis ; Fast, Patricia ; Laufer, Dagna S. ; Cox, Josephine H.

作者单位： Int AIDS Vaccine Initiat, Human Immunol Lab, London, England ^[1] Projet San Francisco, Kigali, Rwanda ^[2] Chelsea & Westminster Healthcare NHS Fdn Trust, London, England ^[3] Univ Tokyo, Tokyo, Japan ^[4] Kenya AIDS Vaccine Initiat Inst Clin Res, Nairobi, Kenya ^[5] ID Pharma, Tsukuba, Ibaraki, Japan ^[6] Emmes Corp, Rockville, MD USA ^[7] Int AIDS Vaccine Initiat, 125 Broad St,9th Fl, New York, NY 10004 USA ^[8]

关键词 replication competent Sendai virus vector HIV-1 vaccine intranasal delivery immunogenicity adenovirus 35 prime-boost mucosal responses

发布时间 2020-03-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交